An official website of the United States government
Home
Name
Bemarituzumab
Alternate Names
None
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
Monoclonal antibody
NSC Number
None
Primary Site
Stomach
Esophagus
Histology
None
Remarks
April 23, 2021 FDA has granted Breakthrough Therapy designation for investigational bemarituzumab as first-line treatment for patients with fibroblast growth factor receptor 2b (FGFR2b) overexpressing and human epidermal growth factor receptor 2-negative metastatic and locally advanced gastric and gastroesophageal adenocarcinoma in combination with modified FOLFOX6 (fluoropyrimidine, leucovorin, and oxaliplatin), based on an FDA-approved companion diagnostic assay showing at least 10% of tumor cells overexpressing FGFR2b.
Coding
This drug should be coded
